NCT02098616View on ClinicalTrials.gov

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Hepatitis C
Interventions
DRUG

DCV/ASV/BMS-791325

Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day

DRUG

DCV/ASV/BMS-791325 + RBV

Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day

Trial Locations (1)

90822

VA Long Beach Healthcare System, Long Beach

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

VA Long Beach Healthcare System

FED

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Timothy Morgan, MD

OTHER